NCT06367283

Metformin Treatment of Patients with Hand Osteoarthritis

Metformin Treatment of Patients with Hand Osteoarthritis: a Randomised, Placebo-controlled Trial

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: Marius Henriksen · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To compare metformin (2 g daily), or maximum tolerated dose, for 16 weeks with placebo as a treatment of hand osteoarthritis symptoms.

Conditions

• Hand Osteoarthritis

Interventions

Type	Name	Description
DRUG	Metformin	Metformin will be initiated at 500 mg once daily with breakfast meal. The dose will be increased with 500 mg every week until 2 g/day is reached, distributed as 1000 mg every morning and evening, together with a meal. If the subject cannot tolerate the maximum dose (2 g/day), the maximal tolerated dose will be given. The treatment period including titration is 16 weeks.
DRUG	Placebo	Participants in the placebo group will receive a placebo tablet identical to the metformin tablet

Timeline

• Start date: 2024-06-03
• Primary completion: 2025-12-01
• Completion: 2026-04-01
• First posted: 2024-04-16
• Last updated: 2025-02-27

Locations

1 site across 1 country: Denmark

Regulatory

• FDA-regulated drug study